...
首页> 外文期刊>Clinical epigenetics. >Changes in DNA methylation at the aryl hydrocarbon receptor repressor may be a new biomarker for smoking
【24h】

Changes in DNA methylation at the aryl hydrocarbon receptor repressor may be a new biomarker for smoking

机译:芳烃受体阻遏物上DNA甲基化的变化可能是吸烟的新生物标记

获取原文
           

摘要

BackgroundSmoking is the largest preventable cause of morbidity and mortality in the United States. In previous work, we demonstrated that altered DNA methylation at the aryl hydrocarbon receptor repressor (AHRR) is correlated with self-reported smoking in 19-year-old African Americans with relatively low levels of smoking. However, one limitation of the prior work is that it was based on self-reported data only. Therefore, the relationship of AHRR methylation to smoking in older subjects and to indicators such as serum cotinine levels remains unknown. To address this question, we examined the relationship between genome- wide DNA methylation and smoking status as indicated by serum cotinine levels in a cohort of 22-year-old African American men. ResultsConsistent with prior findings, smoking was associated with significant DNA demethylation at two distinct loci within AHRR (cg05575921 and cg21161138) with the degree of demethylation being greater than that observed in the prior cohort of 19-year-old smoking subjects. Additionally, methylation status at the AHRR residue interrogated by cg05575921 was highly correlated with serum cotinine levels (adjusted R 2 = 0.42, P ConclusionsWe conclude that AHRR DNA methylation status is a sensitive marker of smoking history and could serve as a biomarker of smoking that could supplement self-report or existing biomarker measures in clinical or epidemiological analyses of the effects of smoking. In addition, if properly configured as a clinical assay, the determination of AHRR methylation could also be used as a screening tool in efforts to target antismoking interventions to nascent smokers in the early phases of smoking.
机译:背景技术吸烟是美国最大的可预防发病率和死亡率的原因。在以前的工作中,我们证明了在吸烟水平相对较低的19岁非裔美国人中,芳烃受体阻遏物(AHRR)的DNA甲基化改变与自我报告的吸烟有关。但是,先前工作的局限性在于它仅基于自我报告的数据。因此,AHRR甲基化与老年受试者吸烟以及诸如血清可替宁水平等指标的关系仍然未知。为了解决这个问题,我们检查了一组22岁非洲裔美国男性的血清可替宁水平,表明全基因组DNA甲基化与吸烟状况之间的关系。结果与先前的发现一致,吸烟与AHRR中两个不同位点(cg05575921和cg21161138)的显着DNA脱甲基有关,其脱甲基程度高于在19岁吸烟受试者的先前队列中观察到的程度。此外,cg05575921询问的AHRR残基的甲基化状态与血清可替宁水平高度相关(调整后的R 2 = 0.42,P结论)我们得出结论,认为AHRR DNA甲基化状态是吸烟史的敏感标志物,可以为吸烟史服务。作为吸烟的生物标志物,可以在吸烟效果的临床或流行病学分析中补充自我报告或现有的生物标志物措施;此外,如果将其正确配置为临床检测手段,则AHRR甲基化的测定也可以用作筛查工具在吸烟的早期阶段针对新生吸烟者采取反吸烟干预措施。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号